Lubrizol LifeSciences and Particle Sciences at AAPS 2017
(Thomson Reuters ONE) -
News Release
Lubrizol LifeSciences and Particle Sciences to Highlight Complex
Drug Product Development and Manufacturing at AAPS 2017
CLEVELAND, November 13, 2017 - The Lubrizol Corporation's LifeSciences business
announces it will highlight the drug product development and manufacturing
capabilities of Particle Sciences Inc. at AAPS 2017 (Booth #1521). Particle
Sciences, a Lubrizol LifeSciences company, is a leading contract development and
manufacturing organization with a comprehensive suite of services for the
formulation, analysis and production of complex drug products such as micro- and
nano-particulates, drug eluting devices, suspensions and emulsions.
Lubrizol LifeSciences continues to expand by investing in commercial drug
product manufacturing at its Bethlehem, Pennsylvania site. Leveraging the
company's knowledge in complex drug product development, the commercial
manufacturing facility is adjacent to the existing facility, offering customers
a seamless flow from early development through commercial supply. This new space
will accommodate both sterile and non-sterile products, highly potent compounds,
controlled substances and organic solvent processing. Attendees can visit the
LifeSciences booth #1521 on Tuesday, November 14 to view a presentation that
will feature additional information about the Particle Sciences expansion.
"With the new investment in over 2,700 square feet of commercial cleanroom
space, we continue to demonstrate our commitment to be the preferred Contract
Development and Manufacturing Organization (CDMO) for complex drug products,"
states Mark Mitchnick M.D., chief executive officer, Particle Sciences, chief
medical officer, Lubrizol LifeSciences. "Our organization has a combination of
in-depth knowledge and resources found nowhere else."
Lubrizol will also feature Transform(TM) Films at AAPS. Transform(TM) films
offer both hydrogel topical film and drug delivery in adhesive systems for wide
API compatibility, increased drug delivery efficiency and comfortable long-
wearing adhesion for dermal and transdermal applications. Attendees can visit
the LifeSciences booth #1521 on Tuesday, November 14 to view a presentation that
will emphasize additional Transform(TM) film capabilities.
About Lubrizol LifeSciences
Lubrizol LifeSciences is a total solutions provider for medical device and
pharmaceutical companies by offering comprehensive products and services,
including innovative materials, drug formulation development, and best-in-class
contract manufacturing solutions. With our long history of polymer expertise in
addition to our downstream acquisition investments, the Lubrizol LifeSciences'
family is positioned to offer a streamlined approach to the development and
production of the next generation of innovative medical and pharmaceutical
solutions.
About The Lubrizol Corporation
The Lubrizol Corporation, a Berkshire Hathaway company, is a market-driven
global company that combines complex, specialty chemicals to optimize the
quality, performance and value of customers' products while reducing their
environmental impact. It is a leader at combining market insights with chemistry
and application capabilities to deliver valuable solutions to customers in the
global transportation, industrial and consumer markets. Lubrizol improves lives
by acting as an essential partner in our customers' success, delivering
efficiency, reliability or wellness to their end users. Technologies include
lubricant additives for engine oils, driveline and other transportation-related
fluids, industrial lubricants, as well as additives for gasoline and diesel
fuel. In addition, Lubrizol makes ingredients and additives for home care,
personal care and skin care products and specialty materials encompassing
polymer and coatings technologies, along with polymer-based pharmaceutical and
medical device solutions.
With headquarters in Wickliffe, Ohio, Lubrizol owns and operates manufacturing
facilities in 17 countries, as well as sales and technical offices around the
world. Founded in 1928, Lubrizol has approximately 8,300 employees worldwide.
Revenues for 2016 were $6.5 billion. For more information, visit Lubrizol.com.
Particle Sciences is part of Lubrizol Advanced Materials, Inc.
Transform(TM) is a trademark of The Lubrizol Corporation.
Media Contact
Ben Patti
(216) 447-5827
Benjamin.patti(at)lubrizol.com
www.lubrizol.com/LifeSciences
###
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Lubrizol via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 13.11.2017 - 18:00 Uhr
Sprache: Deutsch
News-ID 567878
Anzahl Zeichen: 5412
contact information:
Town:
Wickliffe, Ohio
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 289 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Lubrizol LifeSciences and Particle Sciences at AAPS 2017"
steht unter der journalistisch-redaktionellen Verantwortung von
Lubrizol (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
